Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
Status:
Not yet recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX)
and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma
(KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients
with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six
cycles.